[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nader Pouratian\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100566826","deep-brain-stimulation-for-refractory-obsessive-compulsive-disorder-100566826",false,"NCT06660225","Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder","Towards Closed Loop Deep Brain Stimulation for Treatment of Refractory Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* Patients with a diagnosis of obsessive-compulsive disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 criteria\n* Severe OCD assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS) with a score of more than 27\n* Refractory OCD; severe symptoms and impairment for more than 5 years despite pharmacological and psychological treatment.\n* Have failed to improve following treatment with at least two serotonin transport inhibitors and one augmenting agent taken for an adequate time period.\n* Having failed to improve despite adequate cognitive behavioral therapy, as evaluated by the study psychiatrist\n* Patients between 22 and 75.\n* Ability to understand and sign written informed consent by the patient.\n\nExclusion Criteria:\n\n* Diagnosis of severe major depression disorder (MDD) with psychotic features.\n* Significant suicidal risk \\[Hamilton Depression scale item 3 (suicide)\\>2\\].\n* Comorbidity with any primary Psychotic Disorder, Post-Traumatic Stress Disorder (PTSD), or Eating Disorder.\n* History of substance or alcohol dependence or abuse in the preceding 12 months.\n* Significant cognitive decline, measured by Mini-Mental State Examination (MMSE \\\u003C26) and Montreal Cognitive Assessment (MoCA; \\\u003C24).\n* Any other current clinical significant neurological disorder or medical illness affecting brain function, other than a tic disorder.\n* Any clinically significant abnormality on preoperative MRI that would affect the safety of the surgical procedure in the opinion of the study neurosurgeon.\n* Any DBS contraindication, infection, coagulopathy, significant cardiac risk factors, or other medical risk factors for surgery.\n* Pregnancy.","ALL","22 Years","75 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are:\n\n* Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive\u002Fcompulsive symptoms.\n* Map the amSTN using neuronal responses \\[single unit and local field potentials (LFP) recordings\\] at rest and under high frequency stimulation during surgery.\n* Record chronic brain activity with the implanted pulse generator and look for neuronal signatures correlated with symptom severity.\n\nResearchers will compare active deep brain stimulation to a placebo (sham stimulation) to see if DBS works to treat refractory OCD.\n\nParticipants will:\n\n* Undergo surgery for the implantation of a deep brain stimulation device\n* Follow-up visits every three weeks with study staff\n* 6 month follow-up for the next 2-3 years after first year of study participation is complete",[27],"Obsessive-Compulsive Disorder",[29,30,31],"Obsessive","Compulsive","Deep Brain Stimulation","RECRUITING","2026-04-30",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":21},"2026-06",{"date":40,"type":21},"2031-01",{"name":42,"class":43},"Nader Pouratian","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100511221","mindex-a-novel-multifocal-cognitive-brain-machine-interface-system-100511221","NCT05936619","MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System","Inclusion Criteria:\n\n* Paralysis resulting from cervical spinal cord injury (SCI), brainstem stroke (ischemic or hemorrhagic), or amyotrophic lateral sclerosis (ALS)\n* Provide informed consent\n* Understand and comply with instructions, if necessary, with the aid of a translator\n* Communicate via speech or other means\n* Surgical clearance\n* Life expectancy greater than 12 months\n* Travel to study locations up to five days per week for the duration of the study\n* Caregiver monitor for surgical site complications and behavioral changes on a daily basis\n* Psychosocial support system\n* Stable ventilator status\n\nExclusion Criteria:\n\n* Presence of memory problems\n* Intellectual impairment\n* Psychotic illness or chronic psychiatric disorder, including major depression if untreated\n* Poor visual acuity\n* Pregnancy\n* Active infection or unexplained fever\n* Scalp lesions or skin breakdown\n* HIV or AIDS infection\n* Active cancer or chemotherapy\n* Diabetes\n* Autonomic dysreflexia\n* History of seizure\n* Implanted hydrocephalus shunt\n* Prior cranioplasty\n* Other implanted devices\n* Medical conditions contraindicating surgery and chronic implantation of a medical device\n* Unable to undergo MRI or anticipated need for MRI during the study\n* Breastfeeding an infant (direct nursing or via a bottle of expressed milk)\n* Chronic oral or intravenous use of steroids or immunosuppressive therapy\n* Suicidal ideation\n* Drug or alcohol dependence\n* Planning to become pregnant, or unwilling to use adequate birth control","18 Years","65 Years",{"count":54,"type":21},2,[24],"This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender). It utilizes four implanted \"chips\" in the human brain from which investigators can record brain activity during subjects' thoughts and decode meaningful information from this activity to be used as control signals for a computer, a laptop, or a tablet. The use of four brain regions is a significant differentiating feature and scientific innovation of this study over much prior work in this space, that typically derived control signals from one, or sometimes two brain regions. The brain regions to be used here can allow the decode of multiple variables simultaneously, including not just moment-to-moment position, but also high-level goals, intentions, decisions, scene comprehension, and error-related signals involved in natural human behavior. The research is being done through a prospective, longitudinal, single-arm early feasibility study to examine the safety and effectiveness of using MindEx to provide the user an intuitive, efficient, and accurate ability to control multiple applications on a computer interface such as a word processor, a paint application, or to play simple video games. Such versatility could greatly improve the autonomy and quality of life of severely paralyzed individuals. Two subjects will be enrolled, each implanted with MindEx for a period of at least 53 weeks and up to 313 weeks. The study is expected to take at least one year and up to six years in total.",[58],"Paralysis; Quadriplegic",[60,61,62],"spinal cord injury","brain-computer interface","brain-machine interface","2026-03-14",{"date":65,"type":36},"2026-03-17",{"date":67,"type":36},"2026-02-20",{"date":69,"type":21},"2031-09-01",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100358891","tractography-guided-subcallosal-cingulate-deep-brain-stimulation-for-treatment-resistant-depression-100358891","NCT03952962","Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression","Inclusion Criteria:\n\n* Men and women (non-pregnant) between ages 21 and 70;\n* DSM-5 diagnosis a current major depressive episode (MDE) for 10 years of less, recurrent or single episode with first episode after adulthood and did not start during childhood or adolescence, secondary to nonpsychotic unipolar major depressive disorder;\n* Current index MDE ≥24 months duration and\u002For recurrent illness with at least a total of 2 lifetime episodes (including current episode \\>12 months);\n* Treatment resistance (defined by criteria on the Antidepressant Treatment History Form (ATHF)28): Failure to respond to a minimum of four adequate depression treatments from different categories;\n* Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17) ≥20;\n* Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) ≥27 to be met at assessment one week pre-op;\n* Normal brain MRI within 3 months of surgery;\n* Antidepressant medication regimen has been held stable for ≥ 30 days prior to the study screening MADRS;\n* Remain on stable antidepressant medication throughout the study, unless there are safety concerns;\n* Montreal Cognitive Assessment (MoCA) \\>25;\n* Able and willing to give informed consent and agree to attend regular clinic visits for at least 12 months.\n\nExclusion Criteria:\n\n* DSM-5 Axis I Disorders: any lifetime history of psychotic disorder or bipolar disorder;\n* Alcohol or substance use disorder within 6 months, excluding nicotine;\n* History of childhood abuse (physical or sexual) 18\n* Personality disorders;\n* Seeking disability during the trial;\n* Current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or made any suicide attempt within the last year; (MADRS ≥ 5 including the day of surgery);\n* No stable work history;\n* Neurological\u002FMedical condition that makes the patient, in the opinion of the surgeon, a poor candidate;\n\n  1. Pregnant or has plans to become pregnant in the next 36 months;\n  2. Unable\u002Funable to practice birth control through the period of randomization and withdrawal of therapy;\n* Subjects who have a history of a seizure disorder;\n* Subjects who will be exposed to diathermy;\n* Subjects who have any medical contraindications to undergoing DBS surgery (e.g. infection, coagulopathy, or significant cardiac or other medical risk factors for surgery);\n* Subjects with another implanted device such as a cardiac pacemaker, defibrillator or neurostimulator;\n* Subjects who have a history of hemorrhagic stroke;\n* Subjects who are unable to undergo MRI;\n* Subjects who are at increased risk of hemorrhage due to underlying medical conditions or medication.","21 Years","70 Years",{"count":80,"type":21},12,[24],"Treatment resistant depression remains a major problem for individuals and society. Surgical procedures may provide relief for some of these patients. The most frequently considered surgical approach is deep brain stimulation (DBS) of a part of the brain called the subcallosal cingulate region. However, the effectiveness and safety is not well established. The investigators will use a novel approach using advanced imaging technique (magnetic resonance tractography) to evaluate the feasibility and safety of this surgical approach. An innovative method for the definition of DBS target will be applied that redefines the concept of targeting as one of targeting a symptomatic network rather than a structural brain region using subject-based brain anatomy to define the target location. The correlation between imaging findings at baseline with the mood score changes at different time points of the study will be investigated.",[84,85],"Treatment Resistant Depression","Undergoing Deep Brain Stimulation (DBS) Surgery","2025-06-27",{"date":88,"type":36},"2025-07-02",{"date":90,"type":36},"2022-10-28",{"date":92,"type":21},"2027-07",{"name":42,"class":43},""]